WO2003097873A3 - Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications - Google Patents

Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications Download PDF

Info

Publication number
WO2003097873A3
WO2003097873A3 PCT/EP2003/005120 EP0305120W WO03097873A3 WO 2003097873 A3 WO2003097873 A3 WO 2003097873A3 EP 0305120 W EP0305120 W EP 0305120W WO 03097873 A3 WO03097873 A3 WO 03097873A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
methods
polynucleotide
diagnostic
genes
Prior art date
Application number
PCT/EP2003/005120
Other languages
French (fr)
Other versions
WO2003097873A2 (en
Inventor
Heinz Juergen Brockmoeller
Original Assignee
Epidauros Biotechnologie Ag
Heinz Juergen Brockmoeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie Ag, Heinz Juergen Brockmoeller filed Critical Epidauros Biotechnologie Ag
Priority to AU2003240253A priority Critical patent/AU2003240253A1/en
Publication of WO2003097873A2 publication Critical patent/WO2003097873A2/en
Publication of WO2003097873A3 publication Critical patent/WO2003097873A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The present invention relates to a polymorphic 5-Hydroxytryptamine (5-HT) receptor type 3B (HTR3B) polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide of the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.
PCT/EP2003/005120 2002-05-15 2003-05-15 Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications WO2003097873A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003240253A AU2003240253A1 (en) 2002-05-15 2003-05-15 Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010209.1 2002-05-15
EP02010209 2002-05-15

Publications (2)

Publication Number Publication Date
WO2003097873A2 WO2003097873A2 (en) 2003-11-27
WO2003097873A3 true WO2003097873A3 (en) 2004-03-11

Family

ID=29433071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005120 WO2003097873A2 (en) 2002-05-15 2003-05-15 Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications

Country Status (2)

Country Link
AU (1) AU2003240253A1 (en)
WO (1) WO2003097873A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021348A1 (en) * 2004-08-26 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3b (5-ht3b)
CA2716498C (en) 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
LT2801625T (en) 2010-07-02 2018-03-12 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EA027743B1 (en) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077261A1 (en) * 1999-06-16 2000-12-21 The Rockefeller University Susceptibility to neurotransmitter factor dysfunctions detected using plural biological sample arrays
US6462188B1 (en) * 1998-04-16 2002-10-08 The Institute For Genomic Research Human 5-HT3 receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462188B1 (en) * 1998-04-16 2002-10-08 The Institute For Genomic Research Human 5-HT3 receptor
WO2000077261A1 (en) * 1999-06-16 2000-12-21 The Rockefeller University Susceptibility to neurotransmitter factor dysfunctions detected using plural biological sample arrays

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE SNP [online] NCBI; 10 April 2000 (2000-04-10), XP002255280, accession no. SNP Database accession no. rs1176744 *
DUBIN ADRIENNE E ET AL: "The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-HT3B receptor subunit", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 43, 22 October 1999 (1999-10-22), pages 30799 - 30810, XP002236132, ISSN: 0021-9258 *
MEISEL C ET AL: "HOW TO MANAGE INDIVIDUALIZED DRUG THERAPY: APPLICATION OF PHARMACOGENETIC KNOWLEDGE OF DRUG METABOLISM AND TRANSPORT", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, WALTER DE GRUYTER UND CO, DE, vol. 38, no. 9, September 2000 (2000-09-01), pages 869 - 876, XP001030015, ISSN: 1434-6621 *
VEENSTRA-VANDERWEELE JEREMY ET AL: "Pharmacogenetics and the serotonin system: Initial studies and future directions.", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 410, no. 2-3, 2000, pages 165 - 181, XP002255279, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
WO2003097873A2 (en) 2003-11-27
AU2003240253A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
Debouck et al. The impact of genomics on drug discovery
JP2011509073A5 (en)
AU2002224967A1 (en) Identification of genetic determinants of polymorphic cyp3a5 expression
DE50109087D1 (en) SCREENING PROCEDURES
WO2003097873A3 (en) Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
WO2002099099A3 (en) Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications
WO2004018512A3 (en) Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
WO2002059142A3 (en) Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
WO2003014387A3 (en) Polymorphisms in the human gene for cyp1a2 and their use in diagnostic and therapeutic applications
WO2008124170A3 (en) SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES
JP2007508020A5 (en)
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
WO2005123958A3 (en) Cd7 as biomarker and therapeutic target for psoriasis
WO2002024747A3 (en) Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications
DE69734199D1 (en) HUMAN NETRIN-1
JP2004290197A5 (en)
JP2005531290A5 (en)
CN101294198A (en) coronary disease testing method and reagent kit
Roberts et al. Molecular analysis of genotype/phenotype correlations of hypertrophic cardiomyopathy
ES2713162T3 (en) Methods for blood group determination Vel
WO2003083115A1 (en) Abc transporter-associated gene abcc13
JP2001525172A5 (en)
WO2003094860A3 (en) Use of homo sapiens chromosome 1 open reading frame 28 (c1orf28) in the diagnosis of hyperparathyroidism-jaw tumor syndrome
WO2004094638A1 (en) Vasculitis antigen and method of diagnosing vasculitis
CN101294210A (en) coronary disease testing method and reagent kit

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP